EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
14 May 2019

EBE announces the appointment of Michele Antonelli as Vice-President

Brussels, 14 May 2019 – The European Biopharmaceutical Enterprises (EBE) is pleased to announce the appointment of Mr Michele Antonelli, Chief Executive Officer of Stallergenes Greer, as EBE Vice-Pr...

Read more
17 Apr 2019

Health industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships

Brussels, 17 April 2019 The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon...

Read more
26 Nov 2018

Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships

Brussels, 26 November 2018 - Health industries call for a rapid adoption of Horizon Europe, its missions and partnerships  The six undersigned European health industry associations are ambitious...

Read more
12 Aug 2019

EBE-EFPIA Position Paper: An Industry Perspective on Article 117 of the EU Medical Device Regulation: Clinical Requirements for Prefilled, Single-Use, Integral Drug-Device Combination Products

Prefilled, single-use, integral drug-device combinations (DDCs) are regulated as medicinal products. However, the device component needs to conform with “relevant” General Safety and Performance R...

Read more
12 Jun 2019

EBE Reflection Paper: Medicinal product incorporating a drug delivery device component: An Industry Perspective on developing an efficient, ‘End to End’ Control Strategy

A cross-industry working group within EBE (European Biopharmaceutical Enterprises) has recently focused on EU specific topics relating to those integral combination products which are regulated as med...

Read more
17 Dec 2018

EBE Concept Paper – Management and Control of Raw Materials Used in the Manufacture of Biological Medicinal Products and ATMPs

Brussels, 17 December 2018 Effective management and control of raw materials (RM) used in the manufacture of biological medicinal products including advanced therapy medicinal products (ATMPs) requ...

Read more
19 Feb 2019

Exit Strategies for SME Life Science Companies in the EU

When funding life science companies, investors need realistic expectations on how to recover their investment and, potentially, returns on their investment. A number of options exist, commonly c...

Read more
20 Jun 2018

Incentives, IP and Smaller Companies: The Story of uniQure

Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands  and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe geneti...

Read more
07 Jun 2018

KPMG Report: Site Selection for Life Sciences Companies in Europe 2018

EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...

Read more

From Twitter

Our June newsletter is out, with news on our latest Calls for proposals, plus updates from our events this month
Read it online: https://t.co/GZuYVa5kjY
Sign up to receive future issues: https://t.co/mn1Itq02B5
#IMICarryTheTorch #H2020 #EUHealthResearch

Press release: Advanced therapies feature in new IMI Calls for proposals (+ #AI in pathology, healthcare info, health outcomes, cancer trials)
Press release https://t.co/x1qAk8hU5R
Call 18 https://t.co/AMmWuSHFlO
Call 19 https://t.co/oK8plxUyLZ
#H2020 #EUHealthResearch

Eye on Brussels: Read the @EuropeanCancer report from the @EFPIA #OncologyDataSummit last week https://t.co/Z8Rw5esGet #oncology #oncologydata #cancercare

Follow us